Alim Ladha

Alim Ladha is a professional in the field of biological engineering with extensive experience in research and investments. Currently serving at Royalty Pharma since September 2024, Alim previously held positions at MPM BioImpact from September 2021 to September 2024, progressing from Associate to Principal. From 2018 to 2021, Alim was a graduate student at the Broad Institute of MIT and Harvard, contributing to advancements in genome editing and molecular diagnostics through CRISPR, including the development of the STOPCovid diagnostic protocol published in the New England Journal of Medicine. Alim's teaching experience includes roles as a graduate teaching assistant at MIT and as an undergraduate teaching assistant at Duke University. Educational background includes a PhD in Biological Engineering from MIT and a summa cum laude B.S. in Bioengineering and Biomedical Engineering from Duke University.